+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Emergent BioSolutions Inc (EBS) - Product Pipeline Analysis, 2021 Update

Emergent BioSolutions Inc (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products and contract development and manufacturing services. Emergent has a developmental pipeline of candidates targeting dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Emergent BioSolutions Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:


  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Emergent BioSolutions Inc Company Overview
  • Emergent BioSolutions Inc Company Snapshot
  • Emergent BioSolutions Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Emergent BioSolutions Inc - Pipeline Analysis Overview
  • Business Description
  • Emergent BioSolutions Inc - Key Facts
  • Emergent BioSolutions Inc - Major Products and Services
  • Emergent BioSolutions Inc Pipeline Products by Development Stage
  • Emergent BioSolutions Inc Pipeline Products Overview
  • AP003 - Naloxone Multidose Nasal Spray
  • AP003 - Naloxone Multidose Nasal Spray Product Overview
  • AP004 - Naloxone Prefilled Syringe
  • AP004 - Naloxone Prefilled Syringe Product Overview
  • AP007
  • AP007 Product Overview
  • D4 Auto Injector
  • D4 Auto Injector Product Overview
  • Emergard
  • Emergard Product Overview
  • Intranasal SIAN Device
  • Intranasal SIAN Device Product Overview
  • PC2A Auto-Injector
  • PC2A Auto-Injector Product Overview
  • Trobigard
  • Trobigard Product Overview
  • Emergent BioSolutions Inc - Key Competitors
  • Emergent BioSolutions Inc - Key Employees
  • Emergent BioSolutions Inc - Key Employee Biographies
  • Emergent BioSolutions Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Recent Developments
  • Emergent BioSolutions Inc, Recent Developments
Oct 18, 2021: Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
Jul 29, 2021: Emergent BioSolutions Reports Financial Results For Second Quarter 2021
May 06, 2021: Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
Apr 29, 2021: Emergent BioSolutions Reports Financial Results for First Quarter 2021
Apr 15, 2021: Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
Feb 18, 2021: Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Feb 04, 2021: Emergent BioSolutions to release fourth quarter and full year 2020 financial results and conduct a conference call on february 18, 2021
Jan 04, 2021: Emergent BioSolutions to Participate in Investor Conferences
Feb 03, 2020: Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
Jan 13, 2020: Emergent BioSolutions announces preliminary 2019 financial results and provides 2020 financial forecast
Appendix
  • Methodology
  • About The Publisher
  • Contact The Publisher
  • Disclaimer

List of Tables
  • Emergent BioSolutions Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Emergent BioSolutions Inc Pipeline Products by Equipment Type
  • Emergent BioSolutions Inc Pipeline Products by Indication
  • Emergent BioSolutions Inc, Key Facts
  • Emergent BioSolutions Inc, Major Products and Services
  • Emergent BioSolutions Inc Number of Pipeline Products by Development Stage
  • Emergent BioSolutions Inc Pipeline Products Summary by Development Stage
  • AP003 - Naloxone Multidose Nasal Spray - Product Status
  • AP003 - Naloxone Multidose Nasal Spray - Product Description
  • AP004 - Naloxone Prefilled Syringe - Product Status
  • AP004 - Naloxone Prefilled Syringe - Product Description
  • AP007 - Product Status
  • AP007 - Product Description
  • D4 Auto Injector - Product Status
  • D4 Auto Injector - Product Description
  • Emergard - Product Status
  • Emergard - Product Description
  • Intranasal SIAN Device - Product Status
  • Intranasal SIAN Device - Product Description
  • PC2A Auto-Injector - Product Status
  • PC2A Auto-Injector - Product Description
  • Trobigard - Product Status
  • Trobigard - Product Description
  • Emergent BioSolutions Inc, Key Employees
  • Emergent BioSolutions Inc, Key Employee Biographies
  • Emergent BioSolutions Inc, Other Locations
  • Emergent BioSolutions Inc, Subsidiaries
  • Emergent BioSolutions Inc, Joint Venture
  • Glossary

List of Figures
  • Emergent BioSolutions Inc Pipeline Products by Equipment Type
  • Emergent BioSolutions Inc Pipeline Products by Development Stage

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Soligenix Inc
  • Intralytix Inc
  • Genentech USA Inc
  • Merck & Co Inc
  • Elusys Therapeutics Inc
  • Novartis AG
  • Amgen Inc
  • Crucell NV
  • GlaxoSmithKline Plc
  • Mitsubishi Tanabe Pharma Corp